Media Center
CreatiPhage Completes Pre-A Financing, Accelerating the Commercialization of Phage Therapy
Date：2025-04-22
Recently, CreatiPhage (Shanghai) Biotechnology Co., Ltd. (referred to as "CreatiPhage") announced the completion of its Pre-A round of financing, exclusively invested by Xuhui Science and Technology Investment Private Fund Management Co., Ltd. (referred to as "Xuhui STI"). The funds raised will primarily be used to accelerate the market promotion of CreatiPhage's personalized phage therapy and phage-based products, driving the company's breakthrough development in the field of phage therapy.
CreatiPhage is dedicated to addressing bacterial infections in medical, healthcare, and home environments through innovative phage technology. Targeting some of the most challenging superbugs in clinical settings, such as the ESKAPE group (including Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and Enterococcus faecium), as well as difficult-to-treat bacteria like Stenotrophomonas maltophilia, CreatiPhage has successfully established a high-quality lytic phage library and routinely prepares ready-to-use therapeutic phage preparations.
In addition to technological innovation, CreatiPhage has collaborated with multiple medical institutions to advance clinical research on phage therapy and promote its application in hospital infection prevention and control. The company also offers customized phage services and environmental disinfection solutions. Through platforms such as WeChat, Taobao, JD.com, CreatiPhage’s cPhageMarket (霏集®) sells a variety of phage products and technical services. Among them, the "Phagink® 4-in-1" product (now upgraded to "ESKAP 5-in-1") has received funding from the 2024 Shanghai Technology-based SME Technological Innovation Fund Program.
As a pioneer in the field of phage therapy, CreatiPhage not only focuses on technological R&D but also actively promotes industry standardization. In collaboration with the Shanghai Center of Biomedicine Development, the Shanghai Center for Drug Evaluation and Inspection, and Zhongshan Hospital Fudan University, the company has released China's first quality standard for therapeutic phage preparations (Group Standard T/SHPPA 028-2024). Additionally, CreatiPhage participated in the release of quality specifications for veterinary phage preparations (Group Standard T/SHAAV 023-2024) and contributed to the development of multiple expert consensuses and recommendations in the field of phage therapy under the framework of the Phage Alliance in China.
The uniqueness of phage therapy lies in its new types, targets, and mechanisms, as well as its lack of cross-resistance with existing antibiotics. Clinical studies have demonstrated the exceptional safety and efficacy of phage therapy, particularly in personalized treatment. This financing round will further solidify CreatiPhage's leading position in the clinical application of phage therapy and accelerate its industrialization process.
About CreatiPhage
CreatiPhage focuses on developing innovative drugs, personalized therapies, customized technical services, and consumer-grade products based on natural and artificial phages, aiming to address the growing threat of antimicrobial resistance. The company has been recognized as Shanghai’s innovative SME, secured angel round financing from Wenzhou Capital and YS Capital, and won first place in the Life Health Subcategory of the 2023 "Maker in China" Shanghai Division. It was also selected as one of the 2023 Shanghai Top 50 Most Investable Startups.
WeChat Account: 创噬纪CreatiPhage
Website: www.cphage.com
About Xuhui STI
Xuhui Science and Technology Investment Private Fund Management Co., Ltd. (Xuhui STI) is a wholly-owned fund management company under Xuhui Capital (Fund Manager License No.: P1074636). Aligning with both government functions and corporate economic goals, Xuhui STI manages four self-operated funds, providing full lifecycle investment and financing services to foster a virtuous cycle of "technology-industry-finance."
WeChat Account: 徐汇资本
News recommendation
Add: 388 Fenglin Road, Shanghai
Tel: 0086-400-668-7738
©Shanghai ICP reserve No. 2022031782-1 CreatiPhage Biotechnology Co., Ltd. All rights reserved. Designed by JCE
